A top-10 list of critical legal issues that biotech start-ups should make an effort to address, even when the capital squeeze is intense.
Jennifer S. Geetter
Advertisement
Jennifer S. Geetter is a partner at McDermott Will & Emery
Articles by Jennifer S. Geetter
Advertisement
Latest Updated Articles
- Top 10 Legal Issues Biotech Start-Ups Must Address
Published: November 1st 2008 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
